Inclusion Criteria:

          1. Provision of informed consent

          2. Pathologically confirmed non-small cell lung cancer with EGFR exon 19 deletion or exon
             21 L858 mutation.

          3. Clinically or pathologically confirmed stage IIIA- IIIB

          4. Tolerable to complete resection of lung cancer

          5. Able to comply with the required protocol and follow-up procedures, and able to
             receive oral medications

          6. ECOG performance status 0-1.

          7. Life expectancy ≥12 weeks.

          8. Measurable disease must be characterized according to RECIST 1.1 criteria. Measurable
             lesions are defined as those that can be accurately measured in at least one dimension
             as ≥ 10mm by spiral CT scan.

          9. Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and
             Platelet count ≥100 x 109/L, and Hemoglobin ≥10 g/dL (may be transfused to maintain or
             exceed this level).

         10. Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN);
             Aspartate amino transferase (AST) and alanine amino transferase (ALT) ≤ 2.5 x upper
             limit of normal (ULN).

         11. Adequate renal function: Serum creatinine ≤ 1.25 x upper limit of normal (ULN), and
             creatinine clearance≥ 60 ml/min.

         12. Measurable disease according to the preset criteria .

        Exclusion Criteria:

          1. Patients with prior exposure to chemotherapy, irradiation or systemic anti-cancer
             therapy (e.g. monoclonal antibody therapy) for lung cancer.

          2. Known severe hypersensitivity to Icotinib or any of the excipients of this product

          3. Previous or current malignancies of other histologies within the last 5 years with the
             exception of the following: other malignancies cured by surgery alone and having a
             continuous disease-free survival of 5 years; cured basal cell carcinoma of the skin
             and cured in situ carcinoma of the uterine cervix.

          4. Any unstable systemic disease (including active infection, uncontrolled hypertension,
             unstable angina, congestive heart failure, myocardial infarction within six months,
             serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic
             disease).

          5. Interstitial lung disease(ILD) or pulmonary fibrosis; impaired pulmonary function.

          6. Eye inflammation or eye infection not fully treated or predisposing factor of this.

          7. Uncontrolled central nervous system (CNS) metastasis.

          8. Any serious concomitant systemic disorder that, in the opinion of the investigator,
             would compromise the patient's ability to complete the study

          9. Evidence of any other disease, neurological or metabolic dysfunction, physical
             examination or laboratory finding giving reasonable suspicion of a disease or
             condition that contraindicates the use of an investigational drug or puts the subject
             at high risk for treatment-related complications.

         10. Pregnancy or breast feeding.